[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628889":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":39,"locations":45,"responsibleParty":62,"collaborators":64,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":34,"enrollmentInfo":86,"targetDuration":34,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":34,"overallStatus":97,"whyStopped":34,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Consorcio Centro de Investigación Biomédica en Red (CIBER)","OTHER_GOV",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Older adults with at risk MASH who exercise","EXPERIMENTAL","Older adults with Metabolic Dysfunction-Associated SteatoHepatitis aged 70 years or older who will complete the supervised 12-week exercise program.",[13],"Behavioral: Exercise",{"label":15,"type":10,"description":16,"interventionNames":17},"Middle-age adults with at risk MASH who exercise","Middle-aged adults (40 to 60 years old) with at-risk metabolic dysfunction-associated SteatoHepatitis (MASH) who will complete a supervised 12-week exercise program",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Middle-age adults with MASLD who exercise","Middle-aged adults (40 to 60 years old) with metabolic dysfunction-associated steatotic liver disease (MASLD) who will complete a supervised 12-week exercise program.\n\nThis study arm will not recruit new participants. Instead, participants will be selected from a concluded clinical trial (NCT05897073; Study Arm: Experimental - Supervised Exercise Intervention), in which they completed the same exercise program and the same study outcome assessments of the present trial. These participants will be matched by sex, age and potential confounders to the individuals enrolled in the \"Middle-aged adults with at-risk MASH who exercise\" arm of the present study.",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"Middle-age adults with MASLD receiving usual care","ACTIVE_COMPARATOR","Middle-aged adults (40 to 60 years old) with metabolic dysfunction-associated steatotic liver disease (MASLD) who receive usual care.\n\nThis study arm will not recruit new participants. Instead, participants will be selected from a concluded clinical trial (NCT05897073, Study Arm: No Intervention: Usual-care control group), in which they received usual care and the same study outcome assessments of the present trial. These participants will be matched by sex, age and potential confounders to the individuals enrolled in the \"Middle-aged adults with at-risk MASH who exercise\" arm of the present study.",[27],"Behavioral: Usual Care",[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"BEHAVIORAL","Exercise","The exercise intervention will include 2 days\u002Fweek of supervised moderate-high intensity resistance training (rating perceived exertion \\>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \\>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program to achieve a minimum of 135 minutes per week.",[19,15,9],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Usual Care","Participants will receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion.",[23],[40],{"name":41,"role":42,"phone":43,"phoneExt":34,"email":44},"Jose Serra-Rexach, PhD","CONTACT","+34915868835","joseantonio.serra@salud.madrid.es",[46],{"facility":47,"status":34,"city":48,"state":34,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Hospital General Universitario Gregorio Marañon","Madrid","28007","Spain","ES",{"type":53,"coordinates":54},"Point",[55,56],-3.70256,40.4165,{"lat":56,"lon":55},[59],{"name":60,"role":42,"phone":43,"phoneExt":34,"email":61},"Carlos Rodriguez Lopez, PhD","crlopez@salud.madrid.org",{"type":63,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR",[65,67,69,71,73],{"name":47,"class":66},"OTHER",{"name":68,"class":66},"Universidad de Granada",{"name":70,"class":66},"Universidad Politecnica de Madrid",{"name":72,"class":66},"Universidad Complutense de Madrid",{"name":74,"class":75},"Instituto Mixto Universitario Deporte y Salud (iMUDS)","UNKNOWN","100628889","exercise-for-an-aging-liver-exaliver-100628889",false,"NCT07467512","Exercise for an Aging Liver (EXALIVER)","Evaluation of the Impact of Physical Exercise on Metabolic Dysfunction-associated Steatotic Liver Disease in the Elderly","EXALIVER","Inclusion Criteria:\n\n* Middle-aged adults (40 to 60 years old) and older adults (aged 70 years or older)\n* People diagnosed with Metabolic Disfunction-Associated Steatotic Liver Disease (MASLD); defined as the presence of hepatic steatosis (≥5% fat content) in conjunction with at least one cardiometabolic risk factor (overweight or obesity, dysglycaemia or Type II diabetes, elevated plasma triglycerides, reduced HDL-cholesterol or high blood preassure) with no other discernable cause.\n* People diagnosed with at-risk Metabolic Disfunction-Associated SteatoHepatitis (MASH) according to the following criteria: I) a positive liver biopsy (NAS score ≥ 4 points (with at least one point in each of the components of the score: steatosis, lobular inflammation and ballooning, AND significant (F2) or advanced (F3) fibrosis), or II) a FAST score \\>0.65.\n\nExclusion Criteria:\n\n* Descompensated cirrhosis or end-stage liver disease.\n* Other causes of liver disease, such as alcohol abuse or drug-induced, virus-related, or hereditary disease.\n* History of a major adverse cardiovascular event, clinically significant kidney, endocrine, or neurological disease, bariatric surgery, HIV\u002FAIDS, known inflammatory and\u002For rheumatologic disease, cancer, or other medical condition in which exercise is absolute contraindicated.\n* Recent or planned major surgery, as well as anticancer therapies.\n* Participating in a weight loss, a weight-management program or a supervised exercise program (more than 30 minutes three times per week, or 45 minutes twice a week, moderate\u002Fvigorous intensity).\n* Body weight instability. Participants must have maintained the body weight registered at screening visit (tolerance: 5%) for more than 3 months.\n* Regular use of medication or compounds that may affect study outcomes based on research staff criteria.\n* Pregnancy and lactation or planned pregnancy (within the study period).\n* Frequent travel over time zones during the study period.\n* Fear of needles and claustrophobia to magnetic resonance imaging (MRI).\n* Low physical function (ie, ambulation dependency)\n* Being unable to understand and to accept the instructions or the study objectives and protocol.","ALL","40 Years",{"count":87,"type":88},40,"ESTIMATED","INTERVENTIONAL",[91],"NA","The goal of this clinical trial is to learn how physical exercise affects liver health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or at-risk metabolic dysfunction-associated steatohepatitis (MASH); comparing responses between middle-aged adults (40-60 years old) and older adults (70 years and older) of any sex, as well as between participants with low-risk MASLD and high-risk MASH. The main question it aims to answer is:\n\nCould an exercise program reduce liver fat, inflammation and fibrosis, regardless of age and disease severity?\n\nResearchers will compare 4 different groups:\n\nA) older adults with at risk MASH who will exercise B) middle-aged people with at risk MASH who will exercise C) middle-aged people with low-risk MASLD who will exercise D) middle-aged people with low-risk MASLD who will not exercise, receiving usual care.\n\nParticipants in the exercise groups will take part in a supervised 12-week exercise program that includes both strength and aerobic training, completed twice a week.\n\nAll participants, including those receiving usual care, will have health asssessments before and after the 12-week period to measure changes in liver health.",[94,95,96],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","MASH - Metabolic Dysfunction-Associated Steatohepatitis","Liver Fibrosis\u002FNASH","NOT_YET_RECRUITING","2026-03-09",{"date":100,"type":101},"2026-03-12","ACTUAL",{"date":103,"type":88},"2026-03",{"date":105,"type":88},"2027-10",{"name":5,"class":6},1]